Impact of Cardiac Magnetic Resonance Left Atrial Ejection Fraction in Advanced Ischemic Cardiomyopathy.

ischemic cardiomyopathy left atrial ejection fraction patient factors and left atrial function prognostic indices in advanced ICM

Journal

JACC. Advances
ISSN: 2772-963X
Titre abrégé: JACC Adv
Pays: United States
ID NLM: 9918419284106676

Informations de publication

Date de publication:
Feb 2024
Historique:
medline: 29 3 2024
pubmed: 29 3 2024
entrez: 29 3 2024
Statut: ppublish

Résumé

The prognostic significance of cardiac magnetic resonance (CMR)-based left atrial ejection fraction (LAEF) is not well defined in the ischemic cardiomyopathy (ICM) cohort. The authors sought to assess the prognostic impact of LAEF, when adjusted for left ventricular remodeling, myocardial infarct size (MIS), left atrial volume index, and functional mitral regurgitation (FMR), on outcomes in patients with advanced ICM. ICM patients who underwent CMR were retrospectively evaluated (April 2001-December 2019). LAEF, left atrial volume index, MIS, left ventricular remodeling, and FMR were derived from CMR. The primary clinical endpoint was a composite of all-cause mortality and cardiac transplant. A baseline multivariable Cox proportional hazards regression model was constructed to assess prognostic power of LAEF. There were 718 patients (416 primary events) evaluated, with a median duration of follow-up of 1,763 days (4.8 years) and a mean LAEF of 36% ± 15%. On multivariable analysis, higher LAEF was independently associated with reduced risk (HR: 0.24, 95% CI: 0.12-0.48, Reduced LAEF is independently associated with increased mortality in ICM. Risk associated with declining LAEF is continuous and incremental to other risk factors for adverse outcomes in patients with ICM even after adjusting for MIS and FMR severity.

Sections du résumé

BACKGROUND BACKGROUND
The prognostic significance of cardiac magnetic resonance (CMR)-based left atrial ejection fraction (LAEF) is not well defined in the ischemic cardiomyopathy (ICM) cohort.
OBJECTIVES OBJECTIVE
The authors sought to assess the prognostic impact of LAEF, when adjusted for left ventricular remodeling, myocardial infarct size (MIS), left atrial volume index, and functional mitral regurgitation (FMR), on outcomes in patients with advanced ICM.
METHODS METHODS
ICM patients who underwent CMR were retrospectively evaluated (April 2001-December 2019). LAEF, left atrial volume index, MIS, left ventricular remodeling, and FMR were derived from CMR. The primary clinical endpoint was a composite of all-cause mortality and cardiac transplant. A baseline multivariable Cox proportional hazards regression model was constructed to assess prognostic power of LAEF.
RESULTS RESULTS
There were 718 patients (416 primary events) evaluated, with a median duration of follow-up of 1,763 days (4.8 years) and a mean LAEF of 36% ± 15%. On multivariable analysis, higher LAEF was independently associated with reduced risk (HR: 0.24, 95% CI: 0.12-0.48,
CONCLUSIONS CONCLUSIONS
Reduced LAEF is independently associated with increased mortality in ICM. Risk associated with declining LAEF is continuous and incremental to other risk factors for adverse outcomes in patients with ICM even after adjusting for MIS and FMR severity.

Identifiants

pubmed: 38549681
doi: 10.1016/j.jacadv.2023.100796
pmc: PMC10977265
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Chris M Anthony (CM)

Department of Cardiology, The Alfred Hospital, Melbourne, Australia.
Monash Alfred Baker Centre for Cardiovascular Research, Melbourne, Australia.

Tom Kai Ming Wang (TKM)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Imaging Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Donna Salam (D)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Nancy Obuchowski (N)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Mustafa Turkmani (M)

Internal Medicine, McLaren Oakland Program, Pontiac, Michigan, USA.

Danah Al-Deiri (D)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Zoran Popovic (Z)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Imaging Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Brian Griffin (B)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Scott Flamm (S)

Imaging Institute, Cleveland Clinic, Cleveland, Ohio, USA.

David Chen (D)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Christopher Nguyen (C)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Wilson W H Tang (WWH)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Deborah Kwon (D)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Imaging Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Classifications MeSH